Article
Rheumatology
Claire Daien, Marek Krogulec, Paul Gineste, Jean-Marc Steens, Laurence Desroys du Roure, Sophie Biguenet, Didier Scherrer, Julien Santo, Hartmut Ehrlich, Patrick Durez
Summary: This study evaluated the safety and efficacy of ABX464 in patients with moderate-to-severe active rheumatoid arthritis. The results showed that ABX464 at a 50 mg dose was safe, well tolerated, and showed promising efficacy. The 100 mg dose had a high dropout rate due to gastrointestinal adverse events.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Farzin Khosrow-Khavar, Seoyoung C. Kim, Hemin Lee, Su Been Lee, Rishi J. Desai
Summary: The study did not find evidence of increased cardiovascular risk with tofacitinib in patients with RA in a real-world setting. However, tofacitinib was associated with an increased risk of cardiovascular outcomes, although statistically non-significant, in patients with RA with cardiovascular risk factors.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Yu-Jih Su, Hui-Ming Chen, Tien-Ming Chan, Tien-Tsai Cheng, Shan-Fu Yu, Jia-Feng Chen, Chun-Yu Lin, Chung-Yuan Hsu
Summary: This study aimed to investigate whether patients using disease-modifying anti-rheumatic drugs (DMARDs) may have different levels of risk for diabetes and to analyze other risk factors for diabetes. The results showed that certain DMARDs can reduce the risk of diabetes.
Article
Rheumatology
Jeffrey R. Curtis, Kunihiro Yamaoka, Yi-Hsing Chen, Deepak L. Bhatt, Levent M. Gunay, Naonobu Sugiyama, Carol A. Connell, Cunshan Wang, Joseph Wu, Sujatha Menon, Ivana Vranic, Juan J. Gomez-Reino
Summary: This study evaluated malignancies and their associations with baseline risk factors and cardiovascular risk scores in patients with rheumatoid arthritis (RA) treated with tofacitinib and tumour necrosis factor inhibitors (TNFi). The results showed that the risk of malignancies was increased with tofacitinib compared to TNFi, and the highest incidence was observed in patients with a history of atherosclerotic cardiovascular disease (HxASCVD) or increasing cardiovascular risk.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L. Bhatt, Carol A. Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B. Shapiro, Janet E. Pope, Hendrik Schulze-Koops
Summary: This study aimed to characterize infections in patients with rheumatoid arthritis (RA) receiving different treatment regimens. The results showed that tofacitinib had a higher risk of infections compared to tumor necrosis factor inhibitors (TNFi). These findings may provide insights for future treatment decisions.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Kosuke Ebina, Yuki Etani, Yuichi Maeda, Yasutaka Okita, Makoto Hirao, Wataru Yamamoto, Motomu Hashimoto, Koichi Murata, Ryota Hara, Koji Nagai, Yuri Hiramatsu, Yonsu Son, Hideki Amuro, Takayuki Fujii, Takaichi Okano, Yo Ueda, Masaki Katayama, Tadashi Okano, Shotaro Tachibana, Shinya Hayashi, Atsushi Kumanogoh, Seiji Okada, Ken Nakata
Summary: This retrospective study in Japan aimed to assess the retention of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in a real-world cohort of patients with rheumatoid arthritis, as well as identify factors affecting their retention. The study found that biological disease-modifying antirheumatic drugs and Janus kinase inhibitors had higher discontinuation rates due to ineffectiveness, while anti-interleukin-6 receptor antibodies had lower discontinuation rates. The use of oral glucocorticoids was associated with higher rates of discontinuation due to ineffectiveness and toxic adverse events.
Article
Biochemistry & Molecular Biology
Vincenzo Venerito, Pasquale Stefanizzi, Luca Cantarini, Marlea Lavista, Maria Grazia Galeone, Antonio Di Lorenzo, Florenzo Iannone, Silvio Tafuri, Giuseppe Lopalco
Summary: RA patients treated with JAK inhibitors or anti-cellular bDMARDS have an increased risk of herpes zoster (HZ). This prospective study assessed the immunogenicity and safety of the Adjuvanted Recombinant Zoster Vaccine (RZV) in RA patients on JAK inhibitors or anti-cellular bDMARDS. The results showed that RZV vaccination induced a similar immune response in RA patients compared to healthy controls, regardless of the treatment.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2023)
Article
Rheumatology
Roy Fleischmann, Jeffrey R. Curtis, Christina Charles-Schoeman, Eduardo Mysler, Kunihiro Yamaoka, Christophe Richez, Hannah Palac, Deanne Dilley, Jianzhong Liu, Sander Strengholt, Gerd Burmester
Summary: A post hoc analysis was conducted to assess the potential risk of upadacitinib in a high-risk population of patients with rheumatoid arthritis (RA). The results showed that while there was an increased risk of major adverse cardiovascular events (MACE), malignancy (excluding non-melanoma skin cancer), and venous thromboembolism (VTE) in the high-risk populations, the risk was comparable between upadacitinib-treated and adalimumab-treated patients.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Rheumatology
Rene Westhovens, William F. C. Rigby, Desiree van der Heijde, Daniel W. T. Ching, William Stohl, Jonathan Kay, Arvind Chopra, Beatrix Bartok, Franziska Matzkies, Zhaoyu Yin, Ying Guo, Chantal Tasset, John S. Sundy, Angelika Jahreis, Neelufar Mozaffarian, Osvaldo Daniel Messina, Robert B. M. Landewe, Tatsuya Atsumi, Gerd R. Burmester
Summary: The study showed that Filgotinib significantly improved symptoms and physical function in active RA patients treated in combination with MTX, while FIL200 monotherapy did not show a significant advantage in ACR20 response rate compared to MTX.
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Kevin L. Winthrop, Yoshiya Tanaka, Tsutomu Takeuchi, Alan Kivitz, Franziska Matzkies, Mark C. Genovese, Deyuan Jiang, Kun Chen, Beatrix Bartok, Angelika Jahreis, Robin Besuyen, Gerd R. Burmester, Jacques-Eric Gottenberg
Summary: In patients with moderately to severely active rheumatoid arthritis, the safety and tolerability of Filgotinib were good, with a lower incidence of infections in the Filgotinib 200 mg dose group compared to placebo during long-term treatment.
ANNALS OF THE RHEUMATIC DISEASES
(2022)
Article
Rheumatology
Lotte van Ouwerkerk, Patrick Verschueren, Maarten Boers, Paul Emery, Pascal Hendrik Pieter de Jong, Robert B. M. Landewe, Willem Lems, Josef S. Smolen, Tom W. J. Huizinga, Cornelia F. Allaart, Sytske Anne Bergstra
Summary: In patients with rheumatoid arthritis (RA), the use of glucocorticoids (GC) as bridging therapy resulted in a more rapid clinical improvement and fewer changes in medication, but similar long-term GC use compared with patients who did not receive bridging therapy.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Medicine, General & Internal
Elise Descamps, Clemence Gorlier, Sebastien Ottaviani, Elisabeth Palazzo, Philippe Dieude, Marine Forien
Summary: The study found that about one-third of RA patients requiring bDMARDs treatment had oral infections, with 20.9% having dental infections and 14.8% having sinusitis. Active smoking was associated with an increased risk of oral infection, while methotrexate was associated with a reduced risk.
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION
(2021)
Article
Pharmacology & Pharmacy
Merel A. A. Opdam, Sophie Benoy, Lise M. Verhoef, Sandra Van Bijnen, Femke Lamers-Karnebeek, Rene A. M. Traksel, Petra Vos, Alfons A. den Broeder, Jasper Broen
Summary: Patients with inflammatory rheumatic diseases do not have an increased risk for COVID-19 compared to the general population. Older age and obesity are major risk factors for hospitalization for COVID-19 in patients with IRD, while the use of methotrexate may have a protective effect in reducing the risk of hospitalization.
CLINICAL PHARMACOLOGY & THERAPEUTICS
(2022)
Article
Immunology
Maria Luque-Tevar, Carlos Perez-Sanchez, Alejandra Ma Patino-Trives, Nuria Barbarroja, Ivan Arias de la Rosa, M. Carmen Abalos-Aguilera, Juan Antonio Marin-Sanz, Desiree Ruiz-Vilchez, Rafaela Ortega-Castro, Pilar Font, Clementina Lopez-Medina, Montserrat Romero-Gomez, Carlos Rodriguez-Escalera, Jose Perez-Venegas, M. Dolores Ruiz-Montesinos, Carmen Dominguez, Carmen Romero-Barco, Antonio Fernandez-Nebro, Natalia Mena-Vazquez, Jose Luis Marenco, Julia Uceda-Montanez, M. Dolores Toledo-Coello, M. Angeles Aguirre, Alejandro Escudero-Contreras, Eduardo Collantes-Estevez, Chary Lopez-Pedrera
Summary: This study found that RA patients form distinct molecular clusters after receiving anti-TNF therapy, directly linked to their baseline clinical status. The clinical effectiveness of anti-TNF therapy varies among these molecular clusters, correlated with specific modulation of inflammatory response, restoration of altered oxidative status, reduction of NETosis, and reversal of related miRNAs. Integrated analysis of clinical and molecular profiles using machine learning can identify novel signatures as potential predictors of therapeutic response to TNFi therapy.
FRONTIERS IN IMMUNOLOGY
(2021)
Article
Multidisciplinary Sciences
Dao X. Nguyen, Helen M. Baldwin, Amara N. Ezeonyeji, Mohammed Rohan Butt, Michael R. Ehrenstein
Summary: The study revealed that patients with PsA have an increased Th17:Treg ratio, which can be reversed by anti-TNF therapy. Treg from patients treated with different therapies showed contrasting effects on regulating effector T-cell migration, with TNF blockade boosting Treg suppression of migration.
